The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
Globally, there is a persistent shortage (opens in a new tab) of viable organs for transplantation (opens in a new tab). This unmet need has spurred the development of “engineered organs” — cultivated tissue that mimics the structure and function of livers, hearts, lungs and other vital viscera.
While these in-vitro inside parts can be used to fill the gap in organ supply, it’s really hard to supply blood throughout the newly transplanted tissue.
To solve this problem, Bonus Biogroup (opens in a new tab), an Israeli biotechnology company specializing in next-generation tissue regeneration therapies, has developed a method of producing a sophisticated network of artificial blood vessels that will enable reliable blood flow to transplanted artificial organs, drastically increasing their viability.
Bonus BioGroup Founder, CEO, and President Shai Meretzki, COO Dror Ben-David, and VP of R&D Atara Novak are all Technion alumni.